—This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC ...

The mainstay of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) remains a combination of androgen deprivation therapy along with standard-of-care androgen receptors ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity. This ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...